AI drug developer Recursion Pharmaceuticals has brought two more AI-focused companies with their own discovery platforms under its wing in an acquisition worth $87.5 million, the company announced. Recursion is buying both companies, Cyclica and Valence, mostly in equity. Cyclica brings a focus on oncology and central nervous system diseases with an AI-enabled platform that predicts the polypharmacology of small molecules — including how they interact with a wide swath of proteins — in order to advance small molecule drug discovery. The other company it’s acquiring, Valence, has developed AI tools to represent, design and optimize molecules, leveraging new types of chemistry to tackle “previously intractable biology.”
Read the full article: Recursion Acquires Two AI-Based Drug Discovery Companies in $87.5M Deal //
Source: https://endpts.com/recursion-acquires-valence-and-cyclica-two-ai-drug-discovery-companies-for-87-5m